ClearPoint Neuro reported preliminary unaudited revenue of $10.4 million for its fourth quarter of 2025, a 20% increase on a comparable‑sales basis from the $7.8 million recorded in the same period a year earlier. The jump reflects a 23% rise in functional neurosurgery disposables and a 26% rise in biologics and drug‑delivery sales, the two segments that drive the company’s core business.
The company’s management attributed the growth to stronger demand for its MRI‑guided navigation and drug‑delivery solutions, citing new product adoption and expansion into additional markets. The acquisition of IRRAS and its IRRAflow platform, which was not part of the prior year’s comparable period, is expected to further accelerate sales in the intracranial fluid‑management space.
ClearPoint Neuro’s full‑year 2025 revenue is projected to be approximately $37 million, up from $30.5 million in 2024. For 2026, the company has guided revenue between $54 million and $60 million, a 15–20% increase over the 2025 outlook, signaling confidence in continued market penetration and the integration of the IRRAS portfolio.
Gross margin for the quarter was 63%, an improvement from 60% in Q3 2024, but operating and net margins remained negative at –66.3% and –67.4% respectively. The negative margins reflect ongoing investments in research and development, sales and marketing, and the costs associated with integrating the IRRAS acquisition.
CEO Joe Burnett said the preliminary results “return to 20% comparable sales growth, with functional neurosurgery disposables and biologics and drug delivery each growing 23% and 26% respectively.” He added that the company remains focused on expanding its product portfolio while managing the costs of scaling.
Investors responded positively to the announcement, citing the strong revenue beat and optimistic 2026 guidance, while analysts noted that profitability remains a concern as the company continues to invest heavily in growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.